Anzeige
Mehr »
Donnerstag, 25.09.2025 - Börsentäglich über 12.000 News
Geheime Börsenchance: Ist das die bedeutendste Kupferentdeckung Kanadas?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40BRQ | ISIN: US55287L1017 | Ticker-Symbol:
NASDAQ
24.09.25 | 21:59
20,320 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MBX BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
MBX BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur MBX BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:30MBX Biosciences stock down on pricing upsized public offering at $18.00 per share1
03:18MBX Biosciences, Inc.: MBX Biosciences Announces Pricing of Upsized Public Offering41CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
► Artikel lesen
DiFDA clears under-the-skin Keytruda; MBX shares double on study data1
DiMBX Biosciences: Guggenheim hebt Kursziel nach Studienerfolg drastisch auf 84 $ an1
MBX BIOSCIENCES Aktie jetzt für 0€ handeln
MoMBX Biosciences files for public offering of 10 million shares1
MoMBX Biosciences files for public offering of 10M shares1
MoMBX Biosciences, Inc.: MBX Biosciences Announces Proposed Public Offering130CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
► Artikel lesen
MoMBX Biosciences, Inc. - S-1, General form for registration of securities2
MoMBX surges 160% on mid-stage data for hypoparathyroidism drug canvuparatide4
MoMBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise1
MoMBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study1
MoMBX Biosciences, Inc. - 8-K, Current Report1
MoAktie von MBX Biosciences schießt nach Erfolg bei Medikamentenstudie in die Höhe4
MoMBX Biosciences stock soars after hypoparathyroidism drug hits trial goal2
MoMBX Biosciences reports positive Phase 2 results for hypoparathyroidism drug1
MoMBX Biosciences, Inc.: MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension123Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in...
► Artikel lesen
MoWhy MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket2
FrMBX Biosciences, Inc.: MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22142CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
► Artikel lesen
04.09.MBX Biosciences startet Phase-1-Studie für Adipositas-Medikamentenkandidaten1
04.09.MBX Biosciences, Inc. - 8-K, Current Report-
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1